How Will the Biosimilar Market Change in 2018?
Tags: AbbVie,adalimumab,axial spondyloarthritis,biosimilar,Crohn disease,hidradenitis suppurativa,humira,juvenile idiopathic arthritis,pediatric Crohn disease,pediatric plaque psoriasis,psoriatic arthritis,RA,rheumatoid arthritis,Samsung Bioepis,ulcerative colitis,uveitis,specialty pharmacy
“Right now, I think we’re at 7 that have been approved by the FDA, with a couple more in the pipeline. I think, as of 2015, I believe IMS Health came out with something where there were 41 of these in development. So I know that there’s probably more coming on, and I think more will come on once we get some clarity from the FDA about what direction they’re going to do as far as regulating biosimilars, but I don’t think this a trend that’s going away anytime soon. At the end, we all want to lower prices, patients need to be taken care of by specialty pharmacies, and they realize that, and I know patients have become a lot more savvy about what’s out there. So, I think everybody’s really just trying to figure out how are biosimilars going to effect the market, and how much are they going to lower the price?”